Inês Rego de Figueiredo

Dr. Inês Rego de Figueiredo

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 March 2014 in IUBMB Life
Verified
Journal Article
Closed access
PDF file
IFInês Rego de Figueiredo
Inês Rego de Figueiredo
JFJoão Miguel Freire
João Miguel Freire
LFLuís Flores
Luís Flores
AVAna Salomé Veiga
Ana Salomé Veiga
MCMiguel Castanho
Miguel Castanho

28 November 2013 in The FEBS Journal
Verified
Journal Article
Closed access
PDF file
JFJoão M. Freire
João M. Freire
AVAna Salomé Veiga
Ana Salomé Veiga
IFInês Rego de Figueiredo
Inês Rego de Figueiredo
Beatriz G. de la TorreBeatriz G. de la Torre
Beatriz G. de la Torre
Nuno SantosNuno Santos
Nuno Santos
MCMiguel Castanho
Miguel Castanho

30 September 2019 in Pulmonology
Verified
Journal Article
Open access
IFInês Rego de Figueiredo
Inês Rego de Figueiredo
RAR. Vieira Alves
R. Vieira Alves
DBD. Drummond Borges
D. Drummond Borges
MTM. Torres
M. Torres
FLF. Lourenço
F. Lourenço
APA. Panarra
A. Panarra
Pneumocystis pneumonia (PCP) is caused by the fungus Pneumocystis jirovecii, and its incidence has been on the rise in immunosuppressed patients without HIV. We performed a cross sectional study in patients with PCP and assessed demographic, clinical presentation and outcome measures such as mechanical ventilation and mortality differences between HIV and non-HIV patients. The two groups were statistically significantly different, with the HIV group being younger (45.5 years vs 55.9 years, p-value 0.001) and mostly composed of male patients (69% vs 31%, p-value <0.001). Also, the HIV patients had higher percentage of respiratory complaints (90% vs 68%, p-value 0.02) and lactate dehydrogenase elevation (73% vs 40%, p-value 0.001). In contrast, non-HIV patients had worse outcomes with higher incidence of invasive mechanical ventilation (23% vs 46%, p-value 0.005) and in-hospital mortality (13% vs 37%, p-value 0.002). These results reflect the literature and should raise awareness to a potentially fatal medical situation of increasing incidence.

1 January 2017 in Journal of Controlled Release
Verified
Journal Article
Closed access
JFJoão Miguel Freire
João Miguel Freire
IFInês Rego de Figueiredo
Inês Rego de Figueiredo
JVJavier Valle
Javier Valle
AVAna Salomé Veiga
Ana Salomé Veiga
DADavid Andreu
David Andreu
MCMiguel Castanho
Miguel Castanho

27 December 2022 in Nutrition, Metabolism and Cardiovascular Diseases
Verified
Journal Article
Closed access
IFInês Rego de Figueiredo
Inês Rego de Figueiredo
ATAnna Taulaigo
Anna Taulaigo
MVMiguel Vasques
Miguel Vasques
JSJose Silva-Nunes
Jose Silva-Nunes

4 February 2026 in Obesity
Verified
Journal Article
Open access
IFInês Rego de Figueiredo
Inês Rego de Figueiredo
FSFilipa Sofia Simas
Filipa Sofia Simas
AGAngela Ghiletchi
Angela Ghiletchi
JTJoão Oliveira Torres
João Oliveira Torres
JSJosé Silva‐Nunes
José Silva‐Nunes
Objective: This meta‐analysis evaluates the safety and efficacy of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RA) for the treatment of older adults with obesity compared to younger individuals. Methods: A systematic review was conducted following PRISMA guidelines (PROSPERO CRD420251074381). PubMed, Embase, and Scopus were searched until May 17, 2025, for randomized controlled trials and observational studies assessing GLP‐1 RA in adults ≥ 65 years with obesity with or without type 2 diabetes. Random effects meta‐analyses calculated the log odds ratios (LOR) for dichotomous outcomes and the mean differences (MD) for continuous outcomes, with equivalence testing via two one‐sided tests (TOST) and meta‐regression for baseline adjustments. Results: Five studies involving 1229 participants were included. No significant difference in serious adverse events was found between older and younger adults (pooled LOR: 0.06, p = 0.9). Older adults had a trend toward lower frequency of nausea (LOR: −0.44, p = 0.06) but higher incidence of constipation (LOR: 0.72, p = 0.02) and hypoglycemia (LOR: 0.97, p < 0.001). Efficacy in metabolic and weight control was comparable. Additionally, one study suggested that liraglutide could reduce fat mass without worsening sarcopenia. Conclusions: GLP‐1 RA therapy seems to be safe and effective in older adults with obesity, achieving similar effects on weight loss and glycemic control as in younger individuals.